Rowley Law PLLC is investigating potential claims against Quantenna Communications, Inc. (NASDAQ: QTNA) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by ON Semiconductor Corporation (NASDAQ: ON). Stockholders will receive $24.50 for each share of Quantenna Communications, Inc. stock that they hold. The transaction is valued […]
Rowley Law PLLC is investigating potential claims against WABCO Holdings Inc. (NYSE: WBC) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by ZF Friedrichshafen AG. Stockholders will receive $136.50 for each share of WABCO Holdings Inc. stock that they hold. The transaction is valued at approximately […]
Rowley Law PLLC is investigating potential claims against WellCare Health Plans, Inc. (NYSE: WCG) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Centene Corporation (NYSE: CNC). Stockholders will receive $120.00 and 3.38 shares of Centene Corporation common stock for each share of WellCare Health Plans, […]
Rowley Law PLLC is investigating potential claims against HFF, Inc. (NYSE: HF) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Jones Lang LaSalle (NYSE: JLL). Stockholders will receive $24.63 and 0.1505 shares of Jones Lang LaSalle common stock for each share of HFF, Inc. stock […]
Rowley Law PLLC is investigating potential claims against Worldpay, Inc. (NYSE: WP) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Fidelity National Information Services, Inc. (NYSE: FIS). Stockholders will receive $11.00 and 0.9287 shares of Fidelity National Information Services common stock for each share of […]
Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Smith & Nephew plc. Stockholders will receive $19.00 for each share of Osiris Therapeutics, Inc. stock that they hold. The transaction is valued at […]
